Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD: Case 1
Metastatic Prostate Cancer with Charles Ryan, MD and William K. Oh, MD
CASE: Metastatic Prostate Cancer (Part 1)
Stanley S is an 83-year-old Caucasian male whose past medical history includes diagnosis of adenocarcinoma of the prostate in 2012 with no evidence of metastasis. At the time, he was started on bicalutamide and his serum PSA levels subsequently decreased to 1.2 ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
- His serum PSA level is 56.9 ng/ml and his alkaline phosphatase is 258 U/L
- CT scan shows enlarged lumbar bone metastasis with associated soft tissue component, as well as symptomatic nodes with lumbar bone metastases
- Biopsies of the prostate and transrectal ultrasound reveal the prostate is 42 grams
- Ten of 14 cores are positive for prostate cancer for a Gleason score of 8 (4 + 4)
- His ECOG performance status score is a 2
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
Study Sheds Light on Genetic Variations in Advanced Prostate Cancer
February 12th 2024In an interview with Targeted Oncology, Clara Hwang, MD, discussed the notable differences in molecular alterations observed in the retrospective cohort study among Black men with metastatic castration-resistant prostate cancer compared with White men.
Read More
